Virbac has announced that Cortavance, the topical steroid containing HCA, for the symptomatic treatment of inflammatory and pruritic skin disorders in dogs, is now licensed for the control of the symptoms associated with atopy.

Virbac says HCA targets specific affected topical areas with negligible systemic absorption, to provide direct and rapid relief from inflammation and pruritus, delivering significant clinical improvement in atopic cases, both lesion and pruritus scores, after 14 days1.

Cortavance can be applied daily for up to 28 days and included within multimodal treatment plans for prolonged use to control atopy.

Cortavance is presented in a new ergonomic-shaped bottle allowing the user to accurately target the problem area at any angle, with its no-hand-contact spray applicators - 31ml and 76ml sizes.

For further information, contact your local Virbac Territory Manager.

Reference 

  1. Olivry, T., DeBoer, D.J., Favrot, C. et al. Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA). BMC Vet Res 11, 210 (2015). 

Whilst you're here, take a moment to see our latest job opportunities for vets.